WHAT DOES IMMUNOTHERAPY DO FOR LUNG CANCER PATIENT

lung cancer treatment

Immunotherapy is the process of either activating or suppressing the immune system to fight against the disease. The immune therapy that activates the immune response is known as activation immunotherapy and those therapies that decrease or suppress are called suppressive immunotherapy.

In years, immunotherapy is considered as a promising treatment of lung cancer.
It is a type of cancer treatment that activates the immunity to fight against cancer.
It's been decades, researchers have studied the role of the immune system in treating and preventing cancer.

Immunotherapy also can be addressed as biological therapy, is a type of cancer treatment designed to boost the body's natural defenses to fight cancer. The availability of several types of immunotherapy beyond checkpoint inhibitors, including cancer vaccines, monoclonal antibodies, and chimeric antigen receptor (CAR) T cells.

Immunotherapy became a key part of treating several different types of diseases.

But not all immunotherapies work the same way. Some immunotherapies boost your immune system overall, while others try to teach it in order to attack very specific types of cells found in tumors.

In 2015, Nivolumab was used for the treatment of non-small cell lung cancer (NSCLC).

In 2016, Atezolizumab was approved by FDA for treatment of metastatic non-small cell lung cancer (NSCLC).

In 2017, Pembrolizumab in combination with pemetrexed and carboplatin was used for non-small cell lung cancer (NSCLC) And In the year 2018, Atezolizumab was approved.

Targeted Therapy:

Patients who are carrying a lung tumor with EGFR or ALK gene mutations must be treated with targeted therapy rather than immunotherapy initially. For such patients, there is a higher chance that targeted therapy will shrink the tumor than that immunotherapy will work.

Erlotinib (Tarceva): Erlotinib 150 mg is used in the treatment of non-small cell lung cancer (NSCLC). Erlotinib is sold under the trade name Tarceva.

Erlotinib is differentiated as an epidermal growth factor receptor. It is a targeted drug therapy.
The epidermal growth factor receptor (EGFR) found on the surface of normal cells and many cancerous cells are blocked by erlotinib (Erlonat 150 mg).

Some limitations of using this drug are:
  • It is not recommended in use with combination with platinum-based chemotherapy
  • Safety and efficacy are avoided in NSCLC treatment.
Erlotinib tablets should be consumed orally either before or after eating. It is available in different concentrations of 25 mg, 100 mg, and 150 mg.

Some side effects of erlotinib tablets are: 

  • Diarrhea
  • Poor appetite
  • Fatigue
  • Cough
  • Nausea and vomiting
The erlotinib tablets must be consumed under doctor's consent.

Gefitinib: Gefitinib 250mg is a kinase inhibitor that is used in the treatment of metastatic non-small cell lung cancer (NSCLC).

The recommended use of Gefitinib is to uptake 250mg orally either one daily with or without food depending on the stage of the disease.

This 250 mg tablet is biconvex, brown, round having "IRESSA 250" marked on one side. One bottle contains 30 tablets of Gefitinib which should be stored at 20-25 degree Celsius.

Read: Does chemotherapy really cure lung cancer?

Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b
Read more

Difference Between Multiple Myeloma And Leukemia

Image
What is multiple myeloma:  This is also known as plasma cell myeloma or Kahler's disease. It is a cancer in plasma cells that typically produce antibodies. When there is only one tumor present it is called as plasmacytoma and when more than one then called as multiple myeloma. The main cause of myeloma is unknown but the major risk factors are obesity,  inheritance chemicals, radiation, etc. With the effect of cancer, there is an abnormality in plasma cells that produces abnormal antibodies that can cause kidney problems. At the initial stage, there is no sign and symptoms but with the advancement of time bone pain, bleeding, anemia and frequent infections are the common symptoms. Multiple myeloma is diagnosed with the help of blood or urine tests or bone marrow biopsy. And the medication of multiple myeloma includes: Chemotherapy- There are several drugs that are used in the treatment of multiple myeloma such as doxorubicin, etoposide, cisplatin, cyclophosphamide, e
Read more

Lenvatinib Medication Guide

Lenvatinib is recommended for treating patients with locally recurrent, progressive, metastatic, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), together with everolimus for advanced renal cell carcinoma and for hepatocellular carcinoma.  Here are a few important points for patients before taking Lenvatinib:- Female patients who are able to become pregnant must use an effective method of birth control while on the treatment with lenvatinib and for at least 2 weeks after its last dose. Discuss with your doctor about the birth control methods you can use during this time. Lenvatinib is taken at the same time each and every day. If a patient misses any dose, and it cannot be consumed within 12 hours, then that dose must be skipped and the next dose should be consumed at the usual time of administration. The recommended dose is lenvatinib 24 mg (two lenvatinib 10 mg capsules and one lenvatinib 4 mg capsule) orally, taken once in a day, either with or wit
Read more